Healthcare companies Price to FCF
Healthcare companies:
» Price to FCF
» YoY FCF/share growth (%)
$AbbVie(ABBV)$ $Gilead Sciences(GILD)$ $Bristol-Myers Squibb(BMY)$ $Amgen(AMGN)$ $Merck(MRK)$ $Johnson & Johnson(JNJ)$ $Abbott Laboratories(ABT)$ $Medtronic PLC(MDT)$ $Pfizer(PFE)$ $Stryker(SYK)$
Image
It seems that $BMY is potentially the best value here, the chart seems to agree with that statement :-)
From a business point of view the large topic is if the new product portfolio can take off and cover for the ongoing loss in Revlimid and then in 2026 Eliquis and 2028 (2 best selling drugs at $21 B revenue)
https://twitter.com/DividendWave/status/1766917162424225972
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
